Unilife has signed a seven-year contract to supply its Unifill prefilled syringe for use with a generic auto-immune drug.
The unnamed company has exclusive use of the Unifill syringe for a specific indication in Western Europe. In return for exclusivity, which Unilife says will help differentiate the product from brand and generic competitors, the company will pay a fee on top of the unit price to the device maker.
“I am pleased that it contains multiple revenue-generating components, including exclusivity fees, an attractive unit price and significant commercial upside moving forward as other reserved international territories are added,” Alan Shortall, CEO of Unilife, said.
Unilife expects to generate sales of $15m (€12m) a year from the initial Western Europe deal.